Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity

Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity

The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.

Inclusion Criteria:

• Stage I-III breast cancer or lymphoma with a >2 year life expectancy
• A treatment plan that includes anthracyclines and/or trastuzumab
• Age >45 years
• Able to hold breath for 10 seconds
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

• Refusal or inability to provide informed consent
• Known heart failure or LVEF <50%
• Heart rate over 100 bpm
• Renal dysfunction with GFR <30 mL/min/1.73m2
• Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices
• Symptomatic claustrophobia
• Plans to move within 24 months of enrollment